Resmed Inc

Research Resmed Inc (RMD) on Bullrun: valuation model: 20.0% undervalued, market cap USD 28.78B, P/E 19.1, dividend yield 1.2%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerRMD
• ExchangeNYSE
• CountryUnited States
• SectorHealthcare
• IndustryMedical Instruments & Supplies
• CurrencyUSD
• Valuation signal20.0% undervalued
• Market capUSD 28.78B
• P/E19.1
• Dividend yield1.2%
• Financial periodFY2025
• RevenueUSD 5.15B
• Revenue growth9.8%
• Net incomeUSD 1.40B
• Free cash flowUSD 1.66B
• Gross margin59.4%

Valuation Snapshot

Bullrun's latest valuation model marks Resmed Inc as 20.0% undervalued; latest market cap is USD 28.78B; P/E is 19.1; dividend yield is 1.2%.

About Resmed Inc

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software.

Frequently asked questions

Is Resmed Inc overvalued or undervalued?

Bullrun's valuation model currently marks Resmed Inc as 20.0% undervalued.

What is Resmed Inc's market cap?

Resmed Inc's market capitalization is USD 28.78B.

What is Resmed Inc's P/E ratio?

Resmed Inc's price-to-earnings (P/E) ratio is 19.1.

Does Resmed Inc pay a dividend?

Resmed Inc has a dividend yield of 1.2%.

What does Resmed Inc do?

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally.